scholarly journals May Young Elite Cyclists Have Less Efficient Bone Metabolism?

Nutrients ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 1178 ◽  
Author(s):  
Marta Rapún-López ◽  
Hugo Olmedillas ◽  
Alejandro Gonzalez-Agüero ◽  
Alba Gomez-Cabello ◽  
Francisco Pradas de la Fuente ◽  
...  
Keyword(s):  
Young Male ◽  
Adolescent Male ◽  
Type I ◽  
Hydroxyvitamin D ◽  
Amino Terminal ◽  
Type I Procollagen ◽  
Competitive Cyclists ◽  
25 Hydroxyvitamin D ◽  
One Year ◽  
Elite Cyclists

The purpose of this work was to describe changes in metabolic activity in the bones of young male competitive cyclists (CYC) as compared with age-matched controls (CON) over a one-year period of study. Eight adolescent male cyclists aged between fourteen and twenty, and eight age-matched controls participated in this longitudinal study. Serum osteocalcin (OC), amino-terminal propeptide of type I procollagen (PINP), beta-isomerized C-telopeptides (β-CTx) and plasma 25 hydroxyvitamin D [25(OH)D], were investigated by an electrogenerated chemiluminescence immunoassay. Analysis of variance revealed no significant differences in formation and resorption markers between cyclists and controls. Within the groups, both CYC and CON showed decreased OC at −30% and −24%, respectively, and PINP where the figures were −28% and −30% respectively (all p < 0.05). However, only the CYC group showed a decrease in [25(OH)D], lower by 11% (p < 0.05). The similarity in the concentrations of markers in cyclists and controls seems to indicate that cycling does not modify the process of bone remodeling. The decrease in vitamin D in cyclists might be detrimental to their future bone health.

Associations between frailty and serum N-terminal propeptide of type I procollagen and 25-hydroxyvitamin D in older Spanish women: The Toledo Study for Healthy Aging

2015 ◽  
Vol 69 ◽  
pp. 79-84 ◽  
Author(s):  
Ana I. Alvarez-Ríos ◽  
Juan M. Guerrero ◽  
Francisco J. García-García ◽  
Leocadio Rodríguez-Mañas ◽  
Pablo Medrano-Campillo ◽  
...  
Keyword(s):  
Healthy Aging ◽  
Type I ◽  
Hydroxyvitamin D ◽  
Type I Procollagen ◽  
Spanish Women ◽  
25 Hydroxyvitamin D

scholarly journals Low Serum 25-hydroxyvitamin D Level Does Not Adversely Affect Bone Turnover in Prepubertal Children

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3324
Author(s):  
Wojciech J. Bilinski ◽  
Lukasz Szternel ◽  
Joanna Siodmiak ◽  
Przemyslaw T. Paradowski ◽  
Krzysztof Domagalski ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Type I Collagen ◽  
Type I ◽  
Healthy Children ◽  
Strong Positive Correlation ◽  
Hydroxyvitamin D ◽  
Type I Procollagen ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers ◽  
Low Serum

Both vitamin D and insulin-like growth factor 1 (IGF-1) play essential roles in bone metabolism and may interact during prepubertal bone accrual. We investigated the association of low serum 25-hydroxyvitamin D (25(OH)D) (<20 ng/mL) with the circulating bone turnover markers, when compared to their interaction with IGF-1. Subjects and Methods: Serum 25(OH)D, IGF-I, P1NP (N-terminal propeptide of type I procollagen), and CTX-1 (C-terminal telopeptide of type I collagen) were measured, and the bone turnover index (BTI) was calculated in 128 healthy children, aged 9–11 years. Results: Mean 25(OH)D concentration was 21.9 ± 4.9 ng/mL, but in 30.5% of participants it was <20 ng/mL (<50 nmol/L). We observed a trend for higher P1NP (p < 0.05) and IGF-1 (p = 0.08), towards lower 25(OH)D in tertiles. Levels of P1NP in the lowest 25(OH)D tertile (<20 ng/mL) were the highest, while CTX and BTI remained unchanged. Additionally, 25(OH)D negatively correlated with IGF-1, while the correlation with P1NP was not significant. A strong positive correlation of IGF-1 with P1NP and BTI but weak with CTX was observed. Low 25(OH)D (<20 ng/mL) explained 15% of the IGF-1 variance and 6% of the P1NP variance. Conclusions: Low levels of 25(OH)D do not unfavorably alter bone turnover. It seems that serum 25(OH)D level may not be an adequate predictor of bone turnover in children.

COMPARISON BETWEEN THE 5,6-CIS AND 5,6-TRANS ISOMERS OF 25-HYDROXYVITAMIN D3 IN CHRONIC HYPOPARATHYROIDISM

1977 ◽  
Vol 86 (4) ◽  
pp. 784-793 ◽  
Author(s):  
Gerd Offermann ◽  
Dieter Kraft
Keyword(s):  
Serum Calcium ◽  
Calcium Release ◽  
Calcium Absorption ◽  
Intestinal Calcium Absorption ◽  
Normal Range ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
One Year ◽  
Hydroxyproline Excretion ◽  
Chronic Hypoparathyroidism

ABSTRACT Five patients with chronic post-operative hypoparathyroidism were treated with 450 μg/day 5,6-trans-25-hydroxyvitamin D3 (5,6-trans-25OHD3) for 14 days, and the treatment was continued with 150 μg/day for one year. At the end of this period the patients received 450 μg/day 5,6-cis-25-hydroxyvitamin D3 (5,6-cis-25OHD3) for 14 days. Comparison of the effects of both isomers revealed a similar ability to enhance intestinal calcium absorption and to normalize serum calcium; serum phosphate and alkaline phosphatase, however, remained unaffected. Urinary phosphate and hydroxyproline excretion decreased on the cis-isomer and increased on the trans-isomer. During treatment with the lower dose of 5,6-trans-25OHD3 intestinal calcium absorption remained in the normal range for one year, whereas the serum calcium decreased to the levels observed before administration of 450 μg/day within 6 weeks. The results suggest that in hypoparathyroidism 5,6-cis-25OHD3 and 5,6-trans-25OHD3 are equally effective on serum calcium and on intestinal calcium absorption, but that their mode of action on renal phosphate handling and on calcium release from bone is different.

Collagen metabolites in the prediction of response to GH therapy in short children

1997 ◽  
pp. 621-625 ◽  
Author(s):  
P Tapanainen ◽  
M Knip ◽  
L Risteli ◽  
L Kemppainen ◽  
ML Kaar ◽  
...  
Keyword(s):  
Bone Age ◽  
Type I ◽  
Gh Therapy ◽  
Gh Treatment ◽  
Type I Procollagen ◽  
Short Children ◽  
Before And After ◽  
The Absolute ◽  
One Year ◽  
The One

To evaluate the role of collagen metabolites in the prediction of the response to GH treatment we measured the serum concentrations of the C-terminal propeptide of type I procollagen (PICP) and the N-terminal propeptide of type III procollagen (PIIINP) with specific RIAs in 35 short children (16 boys) before and after 5 days, 5 weeks and 3 months of GH therapy. The mean age of the children was 10.3 years (range 1.9-16.4 years) and the bone age ranged from 1.2 to 12.5 years (mean 7.6 years). The initial mean relative height (RH) was -3.6 SDS (range -6.6 to -2.4 S.D.). Nineteen children were found to have GH deficiency (GHD; peak GH responses in two pharmacological tests < 10 micrograms/l), while the remaining 16 were considered to have undefined short stature (USS). The children were treated with recombinant human GH (0.1 U/kg given subcutaneously at bedtime 6-7 times/week). The increases in RHI over the first 6 and 12 months of therapy were used as response measures. There was already a significant increase (P < 0.001) in both the serum PICP and PIIINP levels at 5 days, and the concentrations continued to rise up to 3 months, PICP levels rising less than the PIIINP levels. In the whole group the RHI over 6 months correlated most strongly with the absolute PICP concentrations at 3 months (rS = 0.59; P < 0.05), while the absolute PIIINP concentrations at 3 months showed the strongest relation to the one year RHI (rS = 0.69; P < 0.001). In the GHD group the 6 month RHI was most strongly related to the absolute PICP concentration at 3 months (rS = 0.59; P < 0.05). In the USS group the absolute PICP concentrations at 3 months correlated most strongly with the one year RHI (rS = 0.82; P < 0.01). Significant correlations were also observed between the absolute PIIINP levels at 3 months and the 6 month RHI (rS = 0.60; P < 0.05) and 12 month RHI (rS = 0.76; P < 0.01) in this group. These results show that GH therapy results in an unequivocal increase in circulating concentrations of PICP and PIIINP. The serum PICP and PIIINP concentrations may be of value in the prediction of the long-term response to GH therapy.

scholarly journals Serum Sclerostin Levels Are Decreased in Adult Patients With Different Types of Osteogenesis Imperfecta

2014 ◽  
Vol 99 (2) ◽  
pp. E311-E319 ◽  
Author(s):  
Roland Kocijan ◽  
Christian Muschitz ◽  
Astrid Fahrleitner-Pammer ◽  
Karin Amrein ◽  
Peter Pietschmann ◽  
...  
Keyword(s):  
Body Composition ◽  
Mineral Content ◽  
Adult Patients ◽  
Type I ◽  
Healthy Controls ◽  
Amino Terminal ◽  
Type I Procollagen ◽  
Different Types ◽  
Turnover Markers

Context: There are no specific biochemical bone markers available for osteogenesis imperfecta (OI), and the role of sclerostin as a key regulator of bone formation in OI is unknown. Objectives: We aimed to evaluate the role of sclerostin and its association with bone turnover markers as well as body composition parameters in adult patients with different types of OI. Design, Setting, and Participants: This was a case-control study in 27 adult patients and 50 healthy age- and gender-matched controls. Main Outcome Measures: Serum sclerostin levels and bone turnover markers including serum osteocalcin, amino terminal propeptide of type I procollagen, and CrossLaps as well as body composition parameters were determined in mild OI stage I (OI-I) and moderate-severe OI stages III-IV (OI-III-IV), according to Sillence classification. Data were compared with healthy controls. Results: Sclerostin levels were significantly lower in OI-I (19.9 ± 10.9 pmol/L; P &lt; .001) and OI-III-IV (13.3 ± 10.0 pmol/L; P &lt; .001) compared with healthy adults (45.3 ± 14.9 pmol/L), even after adjustment for age, sex, bone mineral content, and body mass index. CrossLaps and PTH were significantly lower in OI-I (0.197 ± 0.15 ng/L; P = .007 and 33.7 ± 19.1 pg/L; P = .033, respectively) and OI-III-IV (0.221 ± 0.18 ng/L; P = .039, and 27.9 ± 14.7 pg/L; P = .001, respectively) than in healthy controls (0.322 ± 0.15 ng/L and 45.0 ± 16.6 pg/L). Amino-terminal propeptide of type I procollagen was below the reference range for OI-I and OI-III-IV. Patients with OI were shorter and lighter and had a decreased bone mineral content (P &lt; .001) but similar fat distribution and lean body mass, compared with controls. Serum sclerostin levels were not related to any bone marker except osteocalcin, the number of prevalent fractures, or body composition readings. Conclusion: Decreased sclerostin levels in OI might reflect a down-regulation or negative feedback mechanism to prevent further bone loss.

Sign in / Sign up

Export Citation Format

Share Document